December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company dedicated to personalizing cancer care through a novel,…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current…
New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta butterfly symbolism…
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…
Elevates Co-Founder Dhruv Shringi to Executive Chairman; Appoints Siddhartha Gupta as CEONEW DELHI, Nov. 25, 2025 /PRNewswire/ -- Yatra Online…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…